Altimmune, INC Form 4 insider transactions

Altimmune's Chief Medical Officer, Christophe Arbet-Engels, was granted 450,000 stock options and 150,000 Restricted Stock Units.

Altimmune, Inc. Director Catherine A. Sohn was granted 48,800 stock options with an exercise price of $3.92, vesting over 12 months.

Altimmune, Inc. Director Jerome Benedict Durso was granted 48,800 stock options with an exercise price of $3.92, vesting over 12 months.

Altimmune, Inc. Director Teri L Lawver was granted 48,800 stock options with an exercise price of $3.92, vesting over 12 months.

Altimmune Director Diane Jorkasky was granted 48,800 stock options with an exercise price of $3.92, vesting over 12 months.

Altimmune Director John Gill reported the acquisition of 48,800 stock options and a gift of 2,714 common shares, adjusting his direct common stock ownership to zero.

Altimmune, Inc. director Klaus Schafer was granted 48,800 stock options with an exercise price of $3.92, vesting over 12 months starting September 25, 2025.

Altimmune, Inc. Director Mitchel Sayare was granted 48,800 stock options with an exercise price of $3.92, vesting over 12 months starting September 25, 2025.

Altimmune, Inc. Director Philip Hodges was granted 48,800 stock options with an exercise price of $3.92, vesting over 12 months.

Altimmune, Inc. Director Wayne Pisano received a grant of 48,800 stock options with an exercise price of $3.92, vesting over 12 months.

Altimmune's Chief Commercial Officer, Linda M Richardson, was granted 278,000 stock options and 96,000 Restricted Stock Units.

Altimmune's Chief Business Officer, Raymond M. Jordt, acquired 1,368 shares of common stock through the company's Employee Stock Purchase Plan.

Altimmune's Chief Medical Officer, Matthew Scott Harris, acquired 2,018 shares of common stock through the company's Employee Stock Purchase Plan at a discounted price of $3.14 per share.

Altimmune's Chief Scientific Officer, M. Scot Roberts, acquired 846 shares of common stock through the company's Employee Stock Purchase Plan at $3.14 per share.

Director Catherine A. Sohn of Altimmune, Inc. purchased 1,000 shares of common stock at a price of $5.7845 on March 17, 2025.

Altimmune's Chief Financial Officer, Gregory L. Weaver, recently purchased 10,000 shares of the company's common stock at an average price of $5.1996 per share.

Altimmune's Chief Medical Officer, Matthew Scott Harris, transferred 67,787 shares of common stock to the Matthew Scott Harris Trust on March 7, 2025.

Director Teri L. Lawver acquired 69,800 stock options in Altimmune, Inc. on February 24, 2025, according to a Form 4 filing with the SEC.

Altimmune director Jerome Benedict Durso acquired 69,800 stock options on February 24, 2025, exercisable over the next ten years.

Catherine A. Sohn, a director of Altimmune, Inc., reported the acquisition of stock options to purchase 18,600 shares of common stock.

Altimmune's CEO, Vipin K. Garg, reported multiple transactions involving the company's stock, including the vesting of restricted stock units and purchases through the employee stock purchase plan.

Altimmune's Chief Medical Officer, Matthew Scott Harris, reported multiple transactions involving the company's stock, including the vesting of restricted stock units and purchases through the employee stock purchase plan.

Altimmune's Chief Business Officer, Raymond M Jordt, acquired 2,614 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a price of $5.18 per share.

Altimmune's Chief Scientific Officer, M. Scot Roberts, reported multiple transactions involving the company's common stock and restricted stock units.

M. Scot Roberts, Chief Scientific Officer of Altimmune, Inc., reported the acquisition of restricted stock units and stock options, as well as the disposition of shares to cover taxes.

Altimmune's Chief Business Officer, Raymond Jordt, reports the acquisition and disposal of company stock and stock options.

Altimmune's Chief Medical Officer, Matthew Scott Harris, reported the vesting of restricted stock units and the grant of new stock options.

Altimmune's CEO, Vipin K. Garg, has reported the vesting of restricted stock units and the grant of new stock options, resulting in changes to his beneficial ownership of the company's stock.

Raymond Jordt, Chief Business Officer of Altimmune, Inc., reports the vesting of restricted stock units and subsequent tax withholding.

Altimmune's Chief Financial Officer, Gregory L. Weaver, was granted stock options and restricted stock units as part of his compensation.